Refining the definition of hypereosinophilic syndrome.

[1]  P. Weller,et al.  Practical approach to the patient with hypereosinophilia. , 2010, The Journal of allergy and clinical immunology.

[2]  J. Sheikh,et al.  Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. , 2009, The Journal of allergy and clinical immunology.

[3]  M. Majewski,et al.  T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome , 2009, Haematologica.

[4]  P. Valent.  Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. , 2009, Blood reviews.

[5]  H. Simon,et al.  Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. , 2008, The Journal of allergy and clinical immunology.

[6]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[7]  J. Cayuela,et al.  Synchronous FIP1L1–PDGFRA‐positive chronic eosinophilic leukemia and T‐cell lymphoblastic lymphoma: a bilineal clonal malignancy , 2007, European journal of haematology.

[8]  M. Fay,et al.  KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. , 2007, The Journal of allergy and clinical immunology.

[9]  N. Schmitz,et al.  Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma , 2007, Leukemia.

[10]  H. Simon,et al.  Eosinophilic disorders. , 2007, The Journal of allergy and clinical immunology.

[11]  C. Bachert,et al.  Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. , 2006, The Journal of allergy and clinical immunology.

[12]  J. Sheikh,et al.  Cytokine-associated angioedema syndromes including episodic angioedema with eosinophilia (Gleich's Syndrome). , 2006, Immunology and allergy clinics of North America.

[13]  H. Simon,et al.  cIAP‐2 and survivin contribute to cytokine‐mediated delayed eosinophil apoptosis , 2006, European journal of immunology.

[14]  H. Simon,et al.  Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. , 2006, The Journal of allergy and clinical immunology.

[15]  D. Loegering,et al.  Major Basic Protein Homolog (MBP2): A Specific Human Eosinophil Marker1 , 2006, The Journal of Immunology.

[16]  J. Ring,et al.  Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. , 2003, The New England journal of medicine.

[17]  M. Goldman,et al.  The hypereosinophilic syndrome revisited. , 2003, Annual review of medicine.

[18]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[19]  P. Schmid‐Grendelmeier,et al.  High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. , 2002, The Journal of allergy and clinical immunology.

[20]  R. Dummer,et al.  Clinical and Immunological Features of Patients with Interleukin-5-Producing T Cell Clones and Eosinophilia , 2001, International Archives of Allergy and Immunology.

[21]  K. Willard-Gallo,et al.  Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome , 2000, British journal of haematology.

[22]  R. Dummer,et al.  Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. , 1999, The New England journal of medicine.

[23]  S. Wolff,et al.  THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature , 1975, Medicine.